Patient characteristics by regimen
| . | All regimens . | IA regimens . | FA regimens . | TA regimens . |
|---|---|---|---|---|
| Patients | 1279 | 322 | 600 | 357 |
| Inv(16) or t(8;21) | 82 (6%) | 47 (15%) | 14 (2%) | 21 (6%) |
| − 5/− 7 | 340 (27%) | 29 (9%) | 219 (37%) | 92 (26%) |
| Other abnormality | 344 (27%) | 85 (26%) | 178 (30%) | 81 (23%) |
| Normal karyotype | 513 (40%) | 161 (50%) | 189 (32%) | 163 (46%) |
| MDS | 379 (30%) | 57 (18%) | 186 (31%) | 136 (38%) |
| AHD | 575 (45%) | 48 (15%) | 348 (58%) | 179 (50%) |
| Performance status Zubrod 3 or 4 | 149 (12%) | 44 (14%) | 79 (13%) | 26 (7%) |
| Protective environment | 744 (58%) | 146 (41%) | 367 (81%) | 231 (72%) |
| Median age, y (range) | 60 (16-88) | 53 (16-83) | 63 (16-88) | 61 (17-84) |
| Median marrow blast, % (range) | 37 (0-98) | 48.5 (0-97) | 36 (0-96) | 31 (0-98) |
| Median platelet count, × 109/L (range) | 44 (1-2292) | 50 (1-2292) | 40 (1-1355) | 44 (3-708) |
| Median hemoglobin, g/L (range) | 8.0 (2.1-15.1) | 8.15 (2.1-14.4) | 8.0 (2.8-15.1) | 7.6 (2.9-15.0) |
| Median WBC, × 109/L (range) | 8 (0.2-394) | 16.1 (0.4-367.2) | 7 (0.2-245) | 4.1 (0.5-394) |
| Median bilirubin, mg/dL (range) | 0.7 (0-12.1) | 0.6 (0-4.7) | 0.7 (0.1-9.2) | 0.7 (0.2-12.1) |
| . | All regimens . | IA regimens . | FA regimens . | TA regimens . |
|---|---|---|---|---|
| Patients | 1279 | 322 | 600 | 357 |
| Inv(16) or t(8;21) | 82 (6%) | 47 (15%) | 14 (2%) | 21 (6%) |
| − 5/− 7 | 340 (27%) | 29 (9%) | 219 (37%) | 92 (26%) |
| Other abnormality | 344 (27%) | 85 (26%) | 178 (30%) | 81 (23%) |
| Normal karyotype | 513 (40%) | 161 (50%) | 189 (32%) | 163 (46%) |
| MDS | 379 (30%) | 57 (18%) | 186 (31%) | 136 (38%) |
| AHD | 575 (45%) | 48 (15%) | 348 (58%) | 179 (50%) |
| Performance status Zubrod 3 or 4 | 149 (12%) | 44 (14%) | 79 (13%) | 26 (7%) |
| Protective environment | 744 (58%) | 146 (41%) | 367 (81%) | 231 (72%) |
| Median age, y (range) | 60 (16-88) | 53 (16-83) | 63 (16-88) | 61 (17-84) |
| Median marrow blast, % (range) | 37 (0-98) | 48.5 (0-97) | 36 (0-96) | 31 (0-98) |
| Median platelet count, × 109/L (range) | 44 (1-2292) | 50 (1-2292) | 40 (1-1355) | 44 (3-708) |
| Median hemoglobin, g/L (range) | 8.0 (2.1-15.1) | 8.15 (2.1-14.4) | 8.0 (2.8-15.1) | 7.6 (2.9-15.0) |
| Median WBC, × 109/L (range) | 8 (0.2-394) | 16.1 (0.4-367.2) | 7 (0.2-245) | 4.1 (0.5-394) |
| Median bilirubin, mg/dL (range) | 0.7 (0-12.1) | 0.6 (0-4.7) | 0.7 (0.1-9.2) | 0.7 (0.2-12.1) |
IA, idarubicin + ara-C; FA, fludarabine + ara-C; TA, topotecan + ara-c; MDS, myelodysplasia; AHD, antecedent hematologic disorder; WBC, white blood cell.